We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-7 of 7

Drug that is both a salt and an ester of an existing drug is not found to be eligible for data protection
  • Borden Ladner Gervais LLP
  • Canada
  • December 9 2015

The Federal Court has dismissed the judicial review of a decision by Health Canada denying data protection to the applicant for hexaminolevulinate


Data protection regulations apply when comparison added after NDS filed
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2015

In this case, Hospira applied for judicial review of a decision of the Minister of Health, refusing to issue it a Notice of Compliance (NOC) for its


Court upholds minister’s decision to exclude documents from an access to information request on the basis of solicitor-client privilege
  • Borden Ladner Gervais LLP
  • Canada
  • July 29 2015

The Office of the Information Commissioner of Canada (OICC) sought judicial review of the Minister of Health’s refusal to disclose information


Stay granted preventing issuance of NOC pending judicial review application for data protection
  • Borden Ladner Gervais LLP
  • Canada
  • July 15 2015

This is a motion by Horizon for an Order staying the issuance of a Notice of Compliance (NOC) to Horizon for its drug, pursuant to Sections 18(1), 18


Leave denied by Supreme Court of Canada with respect to data protection legislation
  • Borden Ladner Gervais LLP
  • Canada
  • July 18 2011

The Supreme Court of Canada denied leave from a decision of the Federal Court of Appeal finding that the data protection provisions of the Food and Drugs Regulations are intra vires


Restricted Access category in Protective Order denied
  • Borden Ladner Gervais LLP
  • Canada
  • February 7 2011

Novopharm brought a motion seeking a Protective Order that contains a category of “Restricted Access” documents, which senior executives and employees at Nycomed Canada Inc. would not be able to see